Can pemigatinib treat lung cancer?

Pemigatinib, a potent and selective oral inhibitor of FGFR 1-3, has shown antitumor activity in genetically defined tumor models and has demonstrated clinical benefit in patients with tumors harboring certain FGFR alterations. It is approved for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or other rearrangements.

Eligible, molecularly unselected patients with advanced malignancies were enrolled in Part 1 of the study , dose escalation (3+3 design) to determine the maximum tolerated dose (MTD). The Part 2 study (dose expansion) evaluated the recommended phase II dose (RP2D) in tumors associated with FGF/FGFR activity. Overall, 12 partial responses were achieved in the study, the most common of which were 5 cases of cholangiocarcinoma, and various tumors including head and neck cancer, pancreatic cancer, gallbladder cancer, uterine cancer, urothelial cancer, recurrent pilocytic astrocytoma, and non-small cell lung cancer (1 case each). The median response duration was 7.3 months, and patients with FGFR fusion/rearrangement had the highest overall response rate (25.0%), followed by those with FGFR mutations (23.1%).

The original drug of pemetinib has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The price of each box of 4.5mg*14 tablets may be around 30,000 yuan, which is expensive. The price of the original pemetinib drug, 13.5mg*14 tablets, per box sold overseas may be around RMB 70,000 (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas. For example, the price of a box of 4.5mg*21 tablets produced by a Laos pharmaceutical factory may be around 3,000 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The pharmaceutical ingredients of the generic drugs are basically the same as those of the original drugs at home and abroad.